Iron Chelation Therapy in Pediatric Patients

Introduction to Iron Chelation

• The American Society of Hematology recommends iron chelation therapy in pediatric patients when serum ferritin reaches ≥1000 ng/mL or after receiving ≥20 red blood cell transfusions, particularly in those with transfusion-dependent anemias such as β-thalassemia major, sickle cell disease, or myelodysplastic syndromes 1

Initiation Criteria

• The National Comprehensive Cancer Network recommends starting chelation when serum ferritin ≥1000-2500 ng/mL 2, 3, 4
• The American Journal of Hematology suggests starting chelation when the patient has received ≥20 RBC transfusions 3, 4
• The American College of Cardiology recommends starting chelation when cardiac T2* MRI shows significant reduction (indicating cardiac iron loading) 2

Patient Selection

• The American College of Cardiology prioritizes patients with relatively favorable prognosis (low or intermediate-1 risk disease in MDS) for iron chelation therapy 2
• The National Comprehensive Cancer Network recommends prioritizing patients with anticipated ongoing transfusion requirements for iron chelation therapy 3, 4

Available Iron Chelators

• The American College of Cardiology recommends deferoxamine for patients with severe cardiac iron overload or cardiac failure, requiring subcutaneous or intravenous administration 5, 6
• The Journal of the American College of Cardiology suggests deferasirox as a first-line option for pediatric patients ≥2 years of age with transfusional iron overload 5, 6

Monitoring Protocol

• The American Journal of Hematology recommends monitoring serum ferritin every 3 months (monthly if possible) in all transfusion-dependent pediatric patients receiving chelation therapy 1
• The National Comprehensive Cancer Network suggests monitoring renal function, hepatic function, and complete blood count monthly 3, 4

Treatment Goals and Duration

• The National Comprehensive Cancer Network recommends maintaining serum ferritin <1000 ng/mL while preventing organ dysfunction, particularly cardiac and hepatic complications 3, 4, 1
• The American College of Cardiology suggests continuing chelation therapy for several years to completely remove cardiac iron after cardiac failure 7

Disease-Specific Approaches

• The American Journal of Hematology recommends maintaining pre-transfusion hemoglobin 9-10 g/dL and post-transfusion 13-14 g/dL to suppress ineffective erythropoiesis while minimizing iron loading in β-thalassemia major patients 8
• The National Comprehensive Cancer Network suggests chelation therapy for low or intermediate-1 risk MDS with transfusion dependence 2, 3, 4

Iron Chelation Therapy in Pediatric Patients

Indications and Treatment

• Children with sickle cell disease require iron chelation after 12 to 20 transfusions when they are on chronic transfusion programs, as recommended by the American Academy of Pediatrics 9, 10
• Chronic transfusion therapy is most commonly prescribed for primary or secondary stroke prophylaxis in high-risk children, with iron chelation initiated to prevent iron overload 9, 10

Monitoring and Treatment Goals

• Cardiac T2 MRI shows significant reduction indicating cardiac iron loading (T2 <20 ms suggests cardiac iron accumulation), according to the American Heart Association 11
• Cardiac iron removal is very slow, requiring several years of intensive chelation even after resolution of acute cardiac failure, as stated by the American College of Cardiology 11
• The prospective risk of developing heart failure within 1 year is 47% if cardiac T2 is <6 ms, with relative risk of 270 compared to patients with T2 >10 ms, as reported by the American Heart Association 11

Chelation Agents

• Combined therapy with deferoxamine and deferiprone is highly effective for patients with significant iron overload or cardiac involvement, as recommended by the American College of Cardiology 11
• Deferasirox should be avoided in patients with marginal renal perfusion or acute heart failure, according to the American Academy of Pediatrics 11

Deferasirox Dosing for Iron Overload

Initial Dosing Strategy and Indication Criteria

• The American Society of Hematology recommends initiating chelation therapy after approximately 20 red blood cell transfusions in patients with anticipated ongoing transfusion requirements 12
• For myelodysplastic syndromes (MDS), iron chelation should be considered in transfusion-dependent patients with low-risk disease and serum ferritin >1000 ng/mL after approximately 25 units of red cells 12

Disease-Specific Considerations

• In patients with myelodysplastic syndromes (MDS), median survival is >100 months and they are more prone to long-term toxicity from iron overload 13
• Deferasirox is given orally as an alternative to deferoxamine (20-40 mg/kg/day) for secondary iron overload due to dyserythropoiesis 14
• Deferasirox has been used to treat iron overload in hemodialysis patients, though this represents an emerging indication 15, 16

Treatment Duration and Goals

• Long-term management with deferasirox can achieve complete iron removal, particularly for cardiac iron, with median serum ferritin decreasing 23% in the first year, 36.7% by 2 years, and 36.5% by 3 years 12
• Changes in serum ferritin correlate with liver iron concentration reductions 13

Common Pitfalls

• Gastrointestinal disturbances are the most common adverse events, and increased serum creatinine requires monitoring but does not typically necessitate discontinuation 12

Iron Chelation and Transfusion Guidelines for Pediatric Thalassemia Major

Initiation of Chelation Therapy

• The American Society of Hematology recommends beginning iron chelation as soon as regular transfusions are established, after receiving ≥20 red blood cell transfusions, or when serum ferritin reaches ≥1000 ng/mL, with earlier chelation considered for potential hematopoietic stem cell transplant candidates 17, 18

Alternative Chelation Options

• The European Society for Medical Oncology suggests considering deferoxamine (subcutaneous) at 50 mg/kg/day via subcutaneous infusion 5-7 nights per week for patients with severe cardiac iron overload (T2* <10 ms), acute cardiac decompensation, or intolerance to oral chelators 17
• The National Comprehensive Cancer Network recommends deferiprone (oral) at 75 mg/kg/day divided in three doses for combined therapy with deferoxamine in patients with significant cardiac involvement, with consideration of neutropenia risk 17, 19